Diana Bitner, MD, MSCP, FACOG

Articles

Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Women With Breast Cancer Receiving Endocrine Therapy

November 26, 2025

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause

November 26, 2025

Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.

Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms

November 19, 2025

Panelists discuss how dual NK3/NK1 receptor antagonism may expand therapeutic benefits by targeting multiple neural pathways involved in VMS and mood regulation.

Managing Vasomotor Symptoms With NK3 Receptor Antagonism

November 19, 2025

Panelists discuss how NK3 receptor antagonism through fezolinetant offers effective, rapid relief from VMS with a strong safety profile and nonhormonal benefits.

NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms

November 12, 2025

Panelists discuss how NK receptor antagonism provides a targeted, nonhormonal strategy that addresses the physiological root of vasomotor symptoms.

Unmet Needs in Managing Vasomotor Symptoms in Menopause

November 12, 2025

Panelists discuss how limited treatment options and systemic barriers underscore the urgent need for accessible, targeted therapies for vasomotor symptoms.

Impact of Vasomotor Symptoms on Patient Quality of Life

November 05, 2025

Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.

Pathophysiology of Vasomotor Symptoms in Menopause

November 05, 2025

Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.